Safety evaluation of medroxyprogesterone acetate: a pharmacovigilance analysis using FDA adverse event reporting system data.

ABSTRACT:

Background

Medroxyprogesterone acetate (MPA), a synthetic progestogen, is extensively used for the treatment of various conditions, including contraception, irregular menstruation, functional uterine bleeding, and endometriosis. However, like all pharmaceutical agents, MPA is associated with adverse drug reactions. This study aimed to evaluate the adverse events (AEs) associated with MPA in by analyzing real-world data from the U.S. Food and Drug Administration's Adverse Event Reporting System (FAERS). By providing a comprehensive assessment of the safety profile of MPA, this study seeks to support informed clinical decision-making.

Methods

Data covering the period from the first quarter of 2004 to the first quarter of 2024 were collected from the FAERS database. Disproporti

SUBMITTER: Su L 

PROVIDER: S-EPMC11701781 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature